recurrent pituitary tumor
Showing 1 - 25 of >10,000
Recurrent Pituitary Adenomas Trial in New York (Capecitabine, Temozolomide)
Terminated
- Recurrent Pituitary Adenomas
-
New York, New YorkWeill Cornell Medical College
Jul 15, 2022
Acromegaly Due to Pituitary Adenoma Trial in Copenhagen (GIP-A, Placebo)
Recruiting
- Acromegaly Due to Pituitary Adenoma
- GIP-A
- Placebo
-
Copenhagen, DenmarkDepartment of Biomedical Sciences
Nov 1, 2022
Pituitary Tumor Trial in Phoenix, Cleveland (Nasal saline irrigation)
Recruiting
- Pituitary Tumor
- Nasal saline irrigation
-
Phoenix, Arizona
- +1 more
Dec 19, 2022
Clinically Nonfunctioning Pituitary Adenomas
Recruiting
- Pituitary Adenoma
- Pituitary Tumor
- Surgical intervention for CNFA
- Radiotherapy for CNFA
-
New York, New YorkColumbia University Vagelos College of Physicians & Surgeons
Oct 24, 2022
Pituitary Adenoma Trial in Nantong (Excision of pituitary tumor outside pseudocapsule)
Not yet recruiting
- Pituitary Adenoma
- Excision of pituitary tumor outside pseudocapsule
-
Nantong, Jiangsu, ChinaAffiliated Hospital of Nantong University
Jul 19, 2022
Pituitary Adenoma, Pituitary Tumor, Diabetes Insipidus Cranial Type Trial in Leiden (Micro-electrode measurement)
Recruiting
- Pituitary Adenoma
- +3 more
- Micro-electrode measurement
-
Leiden, NetherlandsLeiden University Medical Center
Apr 13, 2022
Hypopituitarism, Radiotherapy-Induced Hypopituitarism, Brain Tumor Trial in Dublin (Dynamic testing of Pituitary Function)
Not yet recruiting
- Hypopituitarism
- +2 more
- Dynamic testing of Pituitary Function
-
Dublin, Ireland
- +1 more
Aug 22, 2023
Pituitary Tumor Surveillance: Pathogenic Correlation
Recruiting
- Pituitary Tumor
-
Los Angeles, CaliforniaCedars-Sinai Medical Center, Pituitary Center
Aug 23, 2021
Pituitary Tumor, Blood Loss, Surgery Trial (Tranexamic acid, Placebo)
Withdrawn
- Pituitary Tumor
- +2 more
- Tranexamic acid
- Placebo
- (no location specified)
Mar 25, 2022
Molecular Study and Precision Medicine for Colorectal Cancer
Not yet recruiting
- Advanced Colorectal Carcinoma
- Recurrent Colorectal Carcinoma
- Molecular Profiling & drug testing in tumor organoids and PDXs
-
Wuhan, Hubei, ChinaWuhan Union Hospital, China
May 30, 2023
Giant Cell Glioblastoma, Recurrent Glioblastoma, Recurrent Gliosarcoma Trial in Rochester (Laboratory Biomarker Analysis,
Active, not recruiting
- Giant Cell Glioblastoma
- +2 more
- Laboratory Biomarker Analysis
- Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine
-
Rochester, MinnesotaMayo Clinic
Jan 4, 2023
Tumor Rebiopsy in Children and Recurrent or Progressive Solid
Active, not recruiting
- Tumor, Solid
- Re-biopsy
- Questionnaire
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Oct 10, 2022
Solid Tumors, Adult Trial (tumor treatment vaccine injection)
Not yet recruiting
- Solid Tumors, Adult
- tumor treatment vaccine injection
- (no location specified)
Feb 16, 2023
International PPB/DICER1 Registry
Recruiting
- Pleuropulmonary Blastoma
- +14 more
-
Minneapolis, MinnesotaChildren's Minnesota
Aug 16, 2022
Glioblastoma, Glioblastoma, IDH-wildtype Trial in Rome (Biomolecular tumor analysis)
Recruiting
- Glioblastoma
- Glioblastoma, IDH-wildtype
- Biomolecular tumor analysis
-
Rome, ItalyFondazione Policlinico Universitario A. Gemelli IRCCS
Mar 6, 2023
Brain Tumor, Primary, Meningioma, Schwannoma Trial in Seoul
Recruiting
- Brain Tumor, Primary
- +4 more
-
Seoul, Korea, Republic ofSeoul National University Hospital
Feb 14, 2022
Endometrial Cancer, Endometrioid Tumor, Cancer Trial in Oklahoma City (nab-sirolimus)
Not yet recruiting
- Endometrial Cancer
- +5 more
-
Oklahoma City, OklahomaUniversity Oklahoma Stephenson Cancer Center
Aug 16, 2023
Pituitary Tumor, ACTH-producing Pituitary Tumour Trial in New York (Pasireotide LAR)
Terminated
- Pituitary Tumor
- ACTH-producing Pituitary Tumour
- Pasireotide LAR
-
New York, New YorkNeuroendocrine Unit and Pituitary Center, Columbia University
Mar 31, 2021
HER2-positive Recurrent or Metastatic Malignant Solid Tumor Trial in Zhengzhou (Recombinant Humanized Bispecific Monoclonal
Recruiting
- HER2-positive Recurrent or Metastatic Malignant Solid Tumor
- Recombinant Humanized Bispecific Monoclonal Antibody MBS301
-
Zhengzhou, ChinaHenan Cancer Hospital
Nov 9, 2022
CNS Tumor, Pediatric, Glioma, Ependymoma Trial in Seattle (EGFR806-specific chimeric antigen receptor (CAR) T cell)
Active, not recruiting
- Central Nervous System Tumor, Pediatric
- +8 more
- EGFR806-specific chimeric antigen receptor (CAR) T cell
-
Seattle, WashingtonSeattle Children's Hospital
Jan 18, 2023